---
document_datetime: 2023-09-21 21:49:46
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/dasatinib-accord-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: dasatinib-accord-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 0.9755363
conversion_datetime: 2025-12-31 05:22:33.615433
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Dasatinib Accord

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                        | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                  |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------|
| IB/0001              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 08/06/2022                                  |                                             | SmPC and PL                      | Sections 4.4 and 4.8 of the SmPC have been updated to add warning on and to include the adverse reaction to chylothorax. |

<!-- image -->

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->